This biotech's problem is that investors became jaded by the slow commercialisation and strategy whoopsies. There are signs of a ...
Vous n'êtes pas connecté
Along with monster fund raising, Telix’s revenue trajectory shows the $6.2bn market cap player has its big boy’s pants ...
This biotech's problem is that investors became jaded by the slow commercialisation and strategy whoopsies. There are signs of a ...
No company wants sub-optimal returns on their product – and pain-management house Medical Developments International is no exception. ...
Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of...
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
In the world of political fund-raising, there is hard money, soft money, dark money — and Leonard Leo money.
Mutual Fund Report for BIPIX
Mutual Fund Report for BIPIX
Swiss and Spanish firms gain joint control of Romanian fertilizer player.
Swiss and Spanish firms gain joint control of Romanian fertilizer player.